Mediolanum International Funds Ltd Buys New Holdings in Evotec SE (NASDAQ:EVO)

Mediolanum International Funds Ltd bought a new stake in Evotec SE (NASDAQ:EVO) during the 3rd quarter, HoldingsChannel reports. The institutional investor bought 140,383 shares of the company’s stock, valued at approximately $512,000.

Several other hedge funds have also recently added to or reduced their stakes in EVO. Vanguard Personalized Indexing Management LLC acquired a new stake in Evotec during the second quarter worth approximately $87,000. Cetera Advisors LLC acquired a new stake in Evotec during the first quarter worth approximately $188,000. DCF Advisers LLC raised its holdings in Evotec by 140.5% during the second quarter. DCF Advisers LLC now owns 114,953 shares of the company’s stock worth $552,000 after purchasing an additional 67,156 shares in the last quarter. Finally, Novo Holdings A S acquired a new stake in Evotec during the second quarter worth approximately $71,183,000. Institutional investors and hedge funds own 5.81% of the company’s stock.

Evotec Stock Down 3.0 %

Shares of Evotec stock opened at $3.52 on Monday. The firm’s fifty day simple moving average is $3.39 and its 200-day simple moving average is $4.41. Evotec SE has a 12 month low of $2.85 and a 12 month high of $12.00. The company has a quick ratio of 1.73, a current ratio of 1.83 and a debt-to-equity ratio of 0.42.

Analyst Ratings Changes

A number of research firms have weighed in on EVO. Morgan Stanley cut shares of Evotec from an “overweight” rating to an “equal weight” rating and cut their price objective for the stock from $15.00 to $6.00 in a report on Monday, July 29th. Deutsche Bank Aktiengesellschaft cut shares of Evotec from a “hold” rating to a “sell” rating in a report on Thursday, August 8th. Jefferies Financial Group cut shares of Evotec from a “buy” rating to a “hold” rating and cut their target price for the company from $8.70 to $3.80 in a report on Monday, October 7th. Finally, HC Wainwright cut their target price on shares of Evotec from $11.00 to $8.00 and set a “buy” rating on the stock in a report on Thursday, August 15th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and two have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $5.93.

Evotec Company Profile

Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as autoimmune diseases, cancer, CNS diseases, diabetes, fibrosis, immunology, infectious diseases, kidney diseases, liver diseases, pain and inflammation, rare diseases, respiratory diseases, tuberculosis, and women’s health.